PRA LEADS NOVEL MULTIPLE MYELOMA DRUG DEVELOPMENT PROGRAM Expanded Access Program Follows Accelerated Approval PR A HEAL TH SCIEN CES CASE STUDYTHE FUTURE OF CLINICAL DEVELOPMENT. PR A HEAL THSCIENCES CASE STUDY SITUATION PRA Health Sciences supported 2 multiple myeloma clinical trials, a Phase III and a “rollover,” for a large biotech client, which enrolled more than 1,100 patients globally at a rate of approximately 0.3 patients/site/month. T

Join for free to read